Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Who cares

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Apr 03, 2024 9:10am

229 Views

Post# 35967234

RE:RE:Who cares

We are still holding because the product is legit. And management is probably working on what ... oh yes I remember ... they are working on value creation for all shareholders. They said that november 2022 if I'm not wrong. At Matt pace it seems! GL

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant